Zymeworks Inc. ZYME 深 滬
已收盤 10-31 16:00:00 美东时间
19.085
-0.035
-0.18%
華盛通- 最 高19.20
- 今 開19.05
- 成交量 34.51万股
- 最 低 18.765
- 昨 收 19.12
- 總市值 14.35亿
- 52周最高 19.98
- 市盈率 靜 --
- 換手率 0.46%
- 52周最低 9.03
- 委 比 -20.00%
- 總股本 7516.62万
- 歷史最高 59.03
- 量 比 0.22
- 振 幅 2.28%
- 歷史最低 4.11
- 每 手 1
- 風險率 1.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多5 Analysts Have This To Say About Zymeworks
Ratings for Zymeworks (NASDAQ:ZYME) were provided by 5 analysts in the past thr...
10-24 20:01
Zymeworks Announces Preliminary Results From Phase 1 Study Evaluating ZW191, ADC Targeting Folate Receptor-Alpha, At AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall
10-24 00:32
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
USA News Group News Commentary – Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is acc...
10-15 21:11
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Zymeworks Inc. announced the acceptance of a poster presentation at the AACR-NCI-EORTC conference, showcasing preliminary results from a Phase 1 study of ZW191, an antibody-drug conjugate targeting folate receptor-⍺, for patients with advanced solid tumors. The study highlights ZW191's potential in ovarian, endometrial, and non-small cell lung cancers, utilizing Zymeworks’ novel payload, ZD06519. The presentation will occur on October 23, 2025, w...
10-13 20:00
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30
B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks (NASDAQ:ZYME) with a Buy rating and announces Price Target of $30.
10-10 21:28
Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements
Zymeworks ( ($ZYME) ) just unveiled an update. Zymeworks Inc. has appointed Dr....
10-09 18:38
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
Zymeworks announced the appointment of Adam Schayowitz, Ph.D., MBA, as Acting Chief Development Officer. Dr. Schayowitz will support the company's pipeline advancement and strategic partnerships while continuing his role at EcoR1 Capital. With nearly 20 years of experience in oncology drug development, Schayowitz brings expertise to accelerate Zymeworks' therapeutic candidates, including ZW251, and enhance partnerships. Zymeworks is focused on im...
10-09 10:00
